Cerenovus Cerepak Detachable Coils Launched in United States

May 1, 2023—Cerenovus, Inc., part of Johnson & Johnson MedTech, announced that its Cerepak detachable coils are commercially available in the United States. The first patient cases have been performed with Cerepak, which is the latest addition to the company’s portfolio of treatments for hemorrhagic stroke.

According to the company, the Cerepak detachable coils are offered in three shapes and multiple coil sizes for comprehensive options to embolize brain aneurysms, including coils shaped specifically to achieve concentric aneurysm filling and contribute large volumetric filling.

Cerepak’s delivery system is designed for ease of use and reliable detachment, next-generation microcatheter stability, effortless tracking through tortuous anatomy, and reduction of radiation exposure from fluoroscopy with fluoro-saver markers.

Patients treated with Cerepak are included in the STERLING registry, which has been collecting real-world data on ruptured and unruptured aneurysms treated with the company’s MicrusFrame and Galaxy coils.

Osama O. Zaidat, MD, and Reade De Leacy, MD, serve as Coprincipal Investigators of the STERLING registry.

“I’m privileged to be one of the first users of the new Cerepak detachable coils,” commented Dr. Zaidat in the company’s press release. “The advancement of greater tools in neurology may improve patient outcomes, and my team looks forward to continuing the utilization of Cerepak coils in our treatment plans.” Dr. Zaidat is Director of the Neuroscience and Stroke Center at Mercy Hospital in Toledo, Ohio.

Dr. De Leacy added, “The Cerepak detachable coils provide important advancements for embolizing brain aneurysms, and we’re pleased to expand the STERLING registry to include this latest Cerenovus offering.” Dr. De Leacy is a neurointerventional radiologist and Associate Professor of Neurosurgery and Radiology at Mount Sinai Health System in New York, New York.